1-[(benzyloxy)(phenyl)methyl]pyrimidine-2,4(1H,3H)-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(benzyloxy)(phenyl)methyl]pyrimidine-2,4(1H,3H)-dione
• 英文别名: 1-[Phenyl(phenylmethoxy)methyl]pyrimidine-2,4-dione
• 化学式: C₁₈H₁₆N₂O₃
• 分子量: 308.337
• InChiKey: LYNSIMCZWJVFCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (Benzyloxy)benzyl chloride 、 尿嘧啶 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以64%的产率得到1-[(benzyloxy)(phenyl)methyl]pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  N -[（苄氧基）（芳基）甲基]取代物作为潜在的HEPT，EBPU和TNK-651类似物的无环核苷的合成

  摘要：

  描述了带有不同N -[（苄氧基）（芳基）甲基]取代基的新型无环核苷5a - 5m的合成方法（方案）。这些化合物可以通过亲电试剂6与嘌呤或嘧啶核碱基或与不同的咪唑衍生物的直接或甲硅烷基辅助偶联而以中等至良好的产率制备。衍生自带正电的电中间体的反应6在氯-抽象是由合理化从头HF / 6-311G量子力学计算。发现正电荷根据芳基取代基的电子性质而不同地分散。

  DOI：

  10.1002/hlca.200790073

文献信息

• [EN] COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES<br/>[FR] COMPOSÉS POUR LA RÉDUCTION DE L'ACTIVITÉ DÉLÉTÈRE DE GÈNES CONTENANT UNE RÉPÉTITION DE NUCLÉOTIDES ÉTENDUE
  申请人：NUREDIS INC

  公开号：WO2020131573A1

  公开（公告）日：2020-06-25

  Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a tetrahydrocarbazole compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.

  本公开内容的方面包括减少目标基因在细胞中的有害影响的方法，例如通过将细胞与有效量的四氢咔唑化合物接触，减少含有突变延伸核苷酸重复序列（NR）的目标基因在细胞中的有害活性。突变延伸NR包含的目标基因的有害活性（例如，由此编码的产物的毒性和/或功能障碍）可以减少，例如，通过减少（在某些情况下包括选择性地减少）由目标基因编码的有毒表达产物（例如，RNA或蛋白质）的生产或活性。还提供了用于实施所述方法的试剂盒和组合物。
• Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US10882821B1

  公开（公告）日：2021-01-05

  Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell, by contacting the cell with an effective amount of an enantiomeric tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.

  本公开的方面包括减少细胞中目标基因的有害影响的方法，例如通过与具有有效量的对映体四氢吲哚胺化合物接触细胞来减少细胞中包含目标基因的突变扩展核苷酸重复（NR）的有害活性。突变扩展NR包含目标基因的有害活性（例如，由其编码的产物的毒性和/或功能障碍）可能通过减少（在某些情况下是差异地，包括选择性地减少）由目标基因编码的有毒表达产物（例如，RNA或蛋白质）的产生或活性来减少。还提供了用于实施该主题方法的试剂盒和组合物。
• [EN] METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES<br/>[FR] PROCEDES DE REDUCTION DE LA TOXICITE D'AGENTS CHIMIOTHERAPEUTIQUES ET ANTIVIRAUX AVEC DES NUCLEOSIDES DE PYRIMIDE ACYLES
  申请人：PRO-NEURON, INC.

  公开号：WO1996040165A1

  公开（公告）日：1996-12-19

  (EN) The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.(FR) La présente invention se rapporte à des composés, des compositions et des procédés de traitement et de prévention de la toxicité due à des agents chimiothérapeutiques et antiviraux. L'invention se rapporte également à des dérivés acylés de nucléosides de pyrimidine non méthylés. Ces composés peuvent atténuer les lésions du système hématopoïétique chez des animaux subissant une chimiothérapie antivirale ou antinéoplasique.

  该发明涉及用于治疗和预防化疗药物和抗病毒药物引起的毒性的化合物、组合物和方法。揭示了非甲基化嘧啶核苷酸的酰化衍生物。这些化合物能够减轻接受抗病毒或抗肿瘤化疗的动物的造血系统损伤。
• TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES
  申请人：——

  公开号：US20010025032A1

  公开（公告）日：2001-09-27

  The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

  本发明涉及化合物、组合物和治疗及预防化疗药物和抗病毒药物毒性的方法。本发明揭示了非甲基嘧啶核苷酸的酰化衍生物。这些化合物能够减轻接受抗病毒或抗肿瘤化疗的动物的造血系统损伤。
• Analyte monitoring and drug delivery
  申请人：Theranos, Inc.

  公开号：EP2319403A2

  公开（公告）日：2011-05-11

  The invention relates to an ingestible, implantable or wearable medical device comprising a microarray which comprises a bioactive agent capable of interacting with a disease marker biological analyte; a reservoir which comprises at least one therapeutic agent and is capable of releasing the therapeutic agent(s) from the medical device; and a plurality of microchips comprising a microarray scanning device capable of obtaining physical parameter data of an interaction between the disease marker biological analyte with the bioactive agent; a biometric recognition device capable of comparing the physical parameter data with an analyte interaction profile; optionally a therapeutic agent releasing device capable of controlling release of the therapeutic agent from the reservoirs; an interface device capable of facilitating communications between the microarray scanning device, biometric recognition device and the therapeutic agent releasing device; and an energy source to power the medical device. Specifically, the invention relates to a medical device capable of detecting an analyte in a bodily fluid comprising at least one microneedle capable of obtaining a sample of a bodily fluid, a first microchannel through which the sample flows and is in fluid communication with the at least one microneedle, a second microchannel in fluid communication with the first microchannel, through which a buffer flows, wherein the second channel comprises a microarray with a bioactive agent, a microarray scanning device to detect an interaction between the bioactive agent and the analyte in the bodily fluid; and an interface device.

  本发明涉及一种可摄取、可植入或可穿戴的医疗设备，该设备包括一个微阵列，该微阵列包括能够与疾病标志物生物分析物相互作用的生物活性剂；一个贮存器，该贮存器包括至少一种治疗剂，并且能够从医疗设备中释放治疗剂；以及多个微芯片，这些微芯片包括一个微阵列扫描装置，该装置能够获取疾病标志物生物分析物与生物活性剂之间相互作用的物理参数数据；生物识别装置，能够将物理参数数据与分析物相互作用曲线进行比较；治疗剂释放装置，能够控制治疗剂从储液器中的释放；接口装置，能够促进微阵列扫描装置、生物识别装置和治疗剂释放装置之间的通信；以及为医疗设备供电的能源。具体而言，本发明涉及一种能够检测体液中分析物的医疗设备，该设备包括至少一个能够获取体液样本的微针、一个样本流经并与至少一个微针流体相通的第一微通道、一个与至少一个微针流体相通的第二微通道、一个与至少一个微针流体相通的第三微通道、一个与至少一个微针流体相通的第四微通道、一个与至少一个微针流体相通的第五微通道、一个与至少一个微针流体相通的第六微通道、一个与第一微通道流体相通的第二微通道，缓冲液流经该第二微通道，其中第二通道包括一个含有生物活性剂的微阵列，一个微阵列扫描装置，用于检测生物活性剂与体液中的分析物之间的相互作用；以及接口装置。